A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Market witnessed bullishness in the initial trading session mainly on the back of favourable cues on the domestic front.

The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

Dr Reddy's CFO Saumen Chakraborty attributed much of the challenges in the US market to price erosion and lower volumes

Dr. Reddy's Lab Q2 results: Consolidated revenue during July-September quarter of this fiscal rose by 26.41 per cent to Rs 4,800.9 crore as against Rs 3,797.8 crore in the year-ago period

Sixteen CEOs and economists lay out a roadmap to revive the economy

The spectacular rise of a reticent man who has pushed his company to the top but still avoids media glare and limelight

The communication also directed the state-level authorities to communicate to the DCGI at the earliest on the action initiated by them.

The move comes after the USFDA asked the company to test the drug for indications of N-nitrosodimethylamine (NDMA) impurity, which the regulator says is a 'probable human carcinogen'

Ranitidine, an old molecule with sales of $412.4 million is found to have cancer-causing impurities

Huawei, the world's biggest maker of such gear, is at the centre of a geopolitical tug-of-war between China and the United States

Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years

Drug regulatory reforms in China have turned the heat on the Indian pharmaceutical industry and raised the cost of bulk drugs. But some firms have managed to turn the crisis into an opportunity by filling in the space left by the Chinese.

Share Market Live: While Sensex fell 184 points to 40,083 with 15 components in the red, Nifty lost 66 points to 12,021.

The Hyderabad-headquartered firm posted a 4 per cent sequential and 14 per cent year-on-year (YoY) growth in revenues at Rs 4,017 crore in Q4FY19

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal, the city-based drug-maker said in a press release.